Dynavax Technologies Stock Price, Forecast & Analysis (NASDAQ:DVAX)

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

Dynavax Technologies Co. (NASDAQ:DVAX) issued its earnings results on Wednesday, November, 6th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.40) by $0.10. The biopharmaceutical company earned $10.58 million during the quarter, compared to analyst estimates of $10.31 million. Dynavax Technologies had a negative return on equity of 399.60% and a negative net margin of 519.95%. Dynavax Technologies's revenue for the quarter was up 624.7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.65) EPS. View Dynavax Technologies' Earnings History.

Dynavax Technologies is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Dynavax Technologies.

5 equities research analysts have issued twelve-month price targets for Dynavax Technologies' shares. Their forecasts range from $13.00 to $20.00. On average, they anticipate Dynavax Technologies' share price to reach $15.33 in the next year. This suggests a possible upside of 159.9% from the stock's current price. View Analyst Price Targets for Dynavax Technologies.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Dynavax Technologies.

Media coverage about DVAX stock has been trending very positive on Wednesday, according to InfoTrie. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Dynavax Technologies earned a media sentiment score of 3.6 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Dynavax Technologies.

Some companies that are related to Dynavax Technologies include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), Medivation (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Array Biopharma (ARRY), United Continental (UAL), Kite Pharma (KITE), Cara Therapeutics (CARA) and Micron Technology (MU).

Dynavax Technologies' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Chicago Capital LLC (6.72%), Rhumbline Advisers (0.15%), Gables Capital Management Inc. (0.10%), California Public Employees Retirement System (0.09%), Commonwealth Equity Services LLC (0.05%) and Ingalls & Snyder LLC (0.02%). Company insiders that own Dynavax Technologies stock include David F Novack, David Louis Johnson, Francis Cano, Michael S Ostrach and Robert Coffman. View Institutional Ownership Trends for Dynavax Technologies.

DVAX stock was bought by a variety of institutional investors in the last quarter, including Chicago Capital LLC, Ingalls & Snyder LLC, California Public Employees Retirement System, Rhumbline Advisers, Gables Capital Management Inc. and Commonwealth Equity Services LLC. View Insider Buying and Selling for Dynavax Technologies.

Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DVAX stock can currently be purchased for approximately $5.90.

Dynavax Technologies has a market capitalization of $494.77 million and generates $8.20 million in revenue each year. The biopharmaceutical company earns $-158,900,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Dynavax Technologies employs 249 workers across the globe.View Additional Information About Dynavax Technologies.

The official website for Dynavax Technologies is http://www.dynavax.com/.

Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected]